Recent analyses on retatrutide, a dual agonist for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, demonstrate encouraging outcomes in managing excess body fat and type 2 diabetic condition. Early data from clinical trials show notable decreases in body bulk and improved